These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 31152883)

  • 1. Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma.
    Mooney J; Bernstock JD; Ilyas A; Ibrahim A; Yamashita D; Markert JM; Nakano I
    World Neurosurg; 2019 Sep; 129():90-100. PubMed ID: 31152883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
    Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
    mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
    Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
    J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma Therapy in the Age of Molecular Medicine.
    Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
    Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting drug resistance in glioblastoma (Review).
    Sherman JH; Bobak A; Arsiwala T; Lockman P; Aulakh S
    Int J Oncol; 2024 Aug; 65(2):. PubMed ID: 38994761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
    Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
    Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of glioblastoma (GBM) molecular classification methods.
    Lee E; Yong RL; Paddison P; Zhu J
    Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
    Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE
    Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Directions in the Treatment of Glioblastoma.
    Reitman ZJ; Winkler F; Elia AEH
    Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells.
    Wang S; Wei W; Yuan Y; Sun B; Yang D; Liu N; Zhao X
    J Transl Med; 2023 Jul; 21(1):493. PubMed ID: 37481592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.